BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
BIND In the News
March 16, 2016
Seven Companies to Watch (From Roundtable Panel Discussion, January 2016)
February 10, 2016
Nano-caging give a failed cancer drug new life
January 2015
Nanomedicine Platform Shows Mettle
June 2014
New Nanomedicines May Better Target Tumors
Boston Business Journal
June 20, 2014
BIND Therapeutics Named One of the Fastest Growing Public Companies by the Boston Business Journal
BostonGlobe January 28, 2013
BIND Goes Small to Make it Big with a Next-Gen Nanoparticle
BostonGlobe January 21, 2013
Bonding with Amgen
BostonGlobe December 19, 2013
Oral Nanoparticles
BostonGlobe August 19, 2013
The Next Wave in ADCs
BostonGlobe July 29, 2013
BIND Doses First Patient in a Study of a Drug for Non-Small Cell Lung Cancer
July 2, 2013
Big Moment for Nanotech: Oncology Therapeutics Poised for a Leap
June 10, 2013
Targeted, Controlled Nanoparticles Being Used to Deliver Docetaxel: Benefits Over Liposomal-Encapsulated Nanoparticle-Based Albumin Targeted Drugs
Fierce Biotech May 30, 2013
BIND-014 Listed as an 'Up-and-Comer' in FierceBiotech "Top 10 Experimental Cancer Drugs of 2013" Report
May 20, 2013
Nano-Vehicles for Cancer Drugs
May 10, 2013
Nanoparticles Offer 'Infinite' Possibilities for Cancer Treatment
BostonGlobe April 23, 2013
Biopharmaceutical Industry Faces a Shift in Dynamics
April 22, 2013
AstraZeneca, BIND Enter $200M+ Cancer Nanomedicine Agreement
Xconomy April 22, 2013
BIND Therapeutics, AstraZeneca Collaborate on Cancer Drug
Boston Business Journal April 22, 2013
Astrazeneca Follows Pfizer for BIND's Second Cancer Nano-Drug Deal of the Month
Boston Herald April 4, 2013
Pfizer 'BINDS' to Accurins in Potential $210M-Plus Deal
Xconomy April 3, 2013
BIND Therapeutics Reels Pfizer into Nanomedicine Partnership
Boston Herald April 3, 2013
Pfizer Makes Nanomedicines Deal With BIND Therapeutics
Boston Herald April 3, 2013
Renamed BIND Therapeutics Strikes Deal with Pfizer
Xconomy January 9, 2013
BIND CEO Says Amgen Deal Marks Nanomedicine Turning Point
January 8, 2013
Amgen in $180.5 Million Drug Development Deal with BIND Biosciences
Fierce Biotech January 8, 2013
Bob Langer Biotech Lands First Big Biopharma Deal with Amgen
Boston Business Journal January 8, 2013
BIND Biosciences Inks $180M Deal with Amgen
Mass High Tech July 16, 2012
BIND Biosciences Taps Former Avila Exec as CFO
Boston Herald April 5, 2012
'I'm Starting to Feel Like My Old Self'
Boston Herald April 5, 2012
Hub Minds, Money Key to Creation of Cancer Drug
Scientific American April 5, 2012
Programmable Nanomedicine Cancer Treatment Shrinks Human Tumors

Emerging Drug Developer: Bind Biosciences (FierceBiotech, January 25, 2010)

Nanotechnology Enables Precise Cancer Targeting (GEN, July 2010)

BIND Banks $12.4M Round as Lead Program Heads into PI (Fierce Biotech, June 2010)

Former J&J Group Chairman's Firm Backs BIND Biosciences in $12.4M Round (Xconomy, June 2010)

Nanoparticle Cancer Therapy Targets Tumours and Dodges immune System ((London)Timesonline, November 2009)

Stealthy Nanoparticles Attack Cancer Cells (Technology Review, November 2009)

BIND Biosciences: Emerging Company Profile (BioCentury, July 2008)

Where Investor Meets Scientist (Wall Street Journal, April 2008) 

BIND Raises $16M For Targeted Nanoparticles In Series B Round (Bioworld, November 2007)

Betting on Nanotech Therapies (Wall Street Journal, September 2007)

Nano Bull's-Eye (Mass High Tech, August 2007)

Top Five Nanotech Breakthroughs of 2006 (Forbes, December 2006)

Tumor-Seeking Nanoparticles (NCI Cancer Bulletin, September 2006)

Cancer Smartbombs (ABC News, May 2006)
Media Inquiries
Direct media inquiries to:
Jeff Boyle

Investor Inquiries
Direct investor inquiries to:
Tom Baker